28% growth masks margin miss; profit growth trails sharply
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 delivered revenue growth but missed EBITDA margin guidance (11.6% vs 12.5%); FY27 growth hedged to 15% despite strong Q1.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong 28% revenue growth and record quarterly scale validate market position, but profit growth of 4.5% severely lags, margins miss guidance at 11.6% vs 12.5%, and PAT down 23.7% QoQ. Management hedged FY27 guidance citing macro uncertainty. Upside from EO supply (Dec 2026), pharma ramp (₹30-50 Cr H2), and B2C exit is real but 2-3 years away; near term remains pressured by freight volatility and raw material hits.
₹697.2 Cr
Revenue · +28.2% YoY₹35.1 Cr
Reported PAT · +4.5% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Highest ever quarterly revenue with 28% YoY growth
MET₹697.2 Cr revenue confirmed; 28% YoY growth matches delivered result
EBITDA margins 12-13% guidance range for FY27
OVERSTATEDQ1 delivered 11.6% EBITDA margin vs 12.5% prior year; miss by ~90-130 bps
Net profit growth supported by diversified portfolio
MISSPAT ₹35.1 Cr +4.5% YoY; growth lags revenue 28% growth by 530 bps; QoQ down 23.7%
Looking at good growth in FY27 with current expansion
OVERSTATEDCFO retreated to 15% growth guidance despite 28% Q1; hedging heavily on macro/geopolitical uncertainty
Core B2B margins 14-15%, excluding B2C drag
METCore B2B EBITDA ₹85 Cr at 14% margin confirmed; signals underlying business healthier than consolidated 11.6%
Earnings quality
What changed since the last call
FY27 guidance hedged despite Q1 beat
DowngradeInitially 15% growth guidance; on strong 28% Q1, management retreated citing 'volatility and uncertainty', stuck to 15% range. Profit growth concern (4.5% vs 28% revenue) signals execution risk.
Margin outlook extended, caveats added
DowngradeTarget 15% EBITDA margins pushed to 2-3 year horizon post-B2C exit; current 11.6% miss vs prior 12-13% guidance. Multiple dependencies: capacity utilization, B2C rationalization, input cost normalization.
Capex guidance withdrawn
WithdrawnPreviously calibrated; now slowed to R&D-only spending post-expansion completion. Saudi Arabia still in early-stage exploratory phase, no timeline.
EO supply timeline clarified
NeutralExpected by Dec 2026, not earlier; FY28 to see full-year benefit. Confirms near-term constraint persists.
The Q&A
Analysts pressed hard on margin trajectory (Divyansh, Disha), EO impact (Sanjesh), and growth deceleration. Management acknowledged challenges but held line on 15% margins within 2-3 years. Some defensiveness on Saudi Arabia (still in 'survey' stage despite being strategic). Tone grew cautious as call progressed; CFO visibly hedging.
EBITDA margin recovery — Divyansh Jaju, Trinetra Asset Managers
PartialCapacity utilization improving, low-margin business exits underway, pharma/aroma expansion planned. Pricing power confirmed but raw material volatility and freight headwinds offset. Next 2 years to show improvement.
Revenue growth guidance — Disha Bhordia, Sapphire Capital
PartialSales growing faster but difficult to predict. Market volatility, geopolitical uncertainty, freight spikes make quarterly forecasting hard. Sticking to 15% on annualized basis.
Margin exit floor — Disha Bhordia, Sapphire Capital
AnsweredYes, expecting same as base level. Exit of low-margin B2C business will push improvement over next 1-2 years.
Thailand plant contribution — Disha Bhordia, Sapphire Capital
Answered₹2-3 Cr Q1 from textile products; small formulation plant (₹10-15 Cr investment). Ramp gradual. Future AHN/HPPC products possible.
Saudi Arabia project — Disha Bhordia, Sapphire Capital
DodgedStill in survey/feedstock allocation stage. No finalization yet. Will announce when decided. Geopolitical uncertainty but conviction intact.
Pharma business ramp — Disha Bhordia, Sapphire Capital
AnsweredStarted few products Q1; compliance-heavy process. Target Q2-Q3 compliance completion. H2 potential ₹30-50 Cr. Steady state ramp over time.
Steady-state margins — Disha Bhordia, Sapphire Capital
AnsweredCore B2B at 14-15% margins today. Target 15% consolidated post-exit once utilization optimizes. Two-year plan.
Volume vs price split — Sanjesh Jain, ICICI Securities
Answered~10% volume growth; rest from pricing. Reflects commodity pass-through mechanics.
Growth lever sans EO — Sanjesh Jain, ICICI Securities
AnsweredNew products (NMMO, biosurfactants, enzymes, trace minerals); pharma ₹50+ Cr; lower-EO formulations with higher non-EO content. Healthy growth despite lean season.
B2C business exit scope — Vinith Jain, Siddh Capital
AnsweredExit consumer B2C only; keeping institutional cleaning products (more profitable). ~₹50 Cr debt in segment. Exit releases 2-3% EBITDA margin.
Institutional margin decline — Sanjesh Jain, ICICI Securities
PartialEBITDA per kilo better metric. Freight volatility, raw material spikes (phenol ₹5 Cr hit), Saudi Arabia seeding costs pressure margins. Focus on EBITDA per kg, consolidate toward 15% plus.
FY27/28 growth outlook — Sanjesh Jain, ICICI Securities
PartialFY27 stick to 15% growth; FY28 should be better with full-year EO availability, pharma ramp, and capacity utilization improvements.
Net debt and interest cost — Rohit Nagraj, 360 One Capital
AnsweredNet debt ₹248 Cr (down from ₹280 Cr in March). Interest higher because prior capex interest was capitalized; now P&L impact. Going forward ₹9-10 Cr run rate.
Asset monetization — Rohit Nagraj, 360 One Capital
AnsweredAndheri office in Unitop's name; assets revalued 5 years ago at market price. Profit element only ₹3.2 Cr in Q1 other income despite ₹10.5 Cr sale price.
B2B distribution investment — Rohit Nagraj, 360 One Capital
AnsweredContinuing investments. Scaling Rossari >2x over 4 years requires market presence. Will not cut seeding to boost near-term EBITDA.
EO capacity utilization — Rohan Picha, Dexter Capital
AnsweredEO capacity ~100% utilized. MDEA continuous plant major investment ramping next 12 months; should see higher margins. EO pricing controlled (sole supplier); margin gain depends on product mix at time of supply.
Guidance
FY27 ~15% growth (unchanged from prior call)
MediumInitially 15% FY27 minimum; Q1 beat at 28% but management hedged on macro/geopolitical volatility. Sticking to 15% annualized.
EBITDA 12-13% FY27; 15% target 2-3 years
LowQ1 delivered 11.6%, below 12-13% range. Contingent on B2C exit (~₹50 Cr debt), capacity utilization normalization, and input cost stabilization.
Capex slowed; selective R&D spend only (pharma, aroma molecules)
MediumLarge capex cycle completed. Focus now on utilization. Saudi Arabia in early exploratory stage; no timeline given.
Risks the call surfaced
Input cost and supply
HighPhenol price spike caused ₹5 Cr loss in Q1; freight costs volatile tied to geopolitical/shipping disruptions. Pricing power exists but lag in pass-through creates margin pressure.
Margin recovery
HighQ1 delivered 11.6% vs 12-13% guidance; B2C drag persists. 2-3 year timeline to reach 15% target contingent on exit and utilization. Risk of further delays.
Profit quality
HighPAT +4.5% YoY vs revenue +28%; QoQ PAT down 23.7%. Profit conversion severely weak. Suggests operational leverage not materializing and cost inflation uncontrolled.
EO supply constraint
MediumEO shortage limits growth in core ethoxylation business; supply expected only by Dec 2026. Until then, growth levers limited to non-EO products and new segments (pharma, aroma).
New initiative execution
MediumThailand plant yielded only ₹2-3 Cr Q1 from ₹10-15 Cr investment. Saudi Arabia still in survey/early stage despite being strategic; geopolitical risk and 1.5-year ramp-up post-announcement.
Management
Score 6/10. Transparent on challenges (phenol loss ₹5 Cr, freight volatility, B2C drag); candid on margin miss vs guidance. But increasingly defensive and hedging on macro uncertainties. Limited detail on Saudi Arabia despite strategic importance (still 'survey' stage). Strong revenue execution (+28% YoY) but profit conversion weak (+4.5% PAT vs 28% revenue). Margin guidance miss (11.6% vs 12-13%). Track record mixed: FY27 full-year guidance hedged to 15% vs prior floor despite Q1 beat.
1 · Dec 2026
EO supply expected; should ease constraint and boost FY28 growth
2 · Q2-Q3 FY27
Pharma compliance ramp-up; target ₹30-50 Cr revenue H2 FY27
3 · H2 FY27
B2C rationalization completion; 2-3% EBITDA margin lift target
Upside from EO supply (Dec 2026), pharma ramp (₹30-50 Cr H2), and B2C exit is real but 2-3 years away; near term remains pressured by freight volatility and raw material hits.
Record growth masks margin compression
₹697 crore revenue hit a record, but profit rose just 4.5% and margins missed guidance. The call reveals management hedging despite the headline beat—a warning sign.
₹697.2 Cr
+28.2% YoY
11.6%
vs 12.5% prior year; guidance 12–13%
₹35.1 Cr
+4.5% YoY; −23.7% QoQ
Rossari posted its highest-ever quarterly revenue of ₹697.2 crore, a muscular 28% year-on-year surge. But here is where the quarter unravels: profit rose only 4.5%, and quarter-on-quarter, net profit fell 23.7%. EBITDA margins landed at 11.6%, a miss against prior guidance of 12–13%. The gap between the headline and what management is actually guiding for defines the story.
Where the profit went missing
Margins remain below their normalized potential. We have already initiated several measures to address this. As these initiatives progress over the next one to two years, we expect a meaningful strengthening in EBITDA performance.
Revenue +28% but profit +4.5% is not a rounding error. It signals that operational leverage has vanished. The company took a ₹5 crore hit from phenol prices in Q1 alone; freight volatility and raw material spikes are eating into pricing power gains. Core B2B EBITDA sits at ₹85 crore (14% margin), suggesting the underlying business is healthier than the consolidated 11.6%. But B2C drag and new ventures—Thailand plant at only ₹2–3 crore contribution from a ₹10–15 crore investment—are pulling consolidated profitability down. Worse, the quarter-on-quarter profit decline of 23.7% screams that near-term headwinds remain unabated.
Highest ever quarterly revenue with 28% YoY growth
Supported₹697.2 Cr confirmed; 28% YoY growth matches delivered result
EBITDA margins 12–13% for FY27
OverstatedQ1 delivered 11.6% vs 12.5% prior year; miss by 90–130 bps
Net profit growth supported by diversified portfolio
ContradictedPAT +4.5% YoY; growth trails revenue 28% by over 20 points; QoQ down 23.7%
Good growth outlook for FY27 with current expansion
OverstatedCFO retreated to 15% FY27 guidance despite Q1 beat; heavily hedging macro/geopolitical uncertainty
Core B2B margins 14–15%, excluding B2C drag
SupportedCore B2B EBITDA ₹85 Cr at 14% margin confirmed; signals underlying business stronger than consolidated
What changed on this call
Three strategic retreats stand out. First: margin outlook. Management pushed the 15% EBITDA target out to 2–3 years post-B2C exit; today's 11.6% is now the stated "floor," far from the prior 12–13% range. Second: capex guidance walked back entirely; capex is now "calibrated to R&D only" with major growth capex complete. Third: FY27 growth hedged to 15% annualized despite 28% Q1—the CFO explicitly retreated when pressed, a signal of waning confidence. On the positive side, EO supply is now confirmed for December 2026, which should unlock growth in FY28. But Saudi Arabia, billed as strategic, remains in "survey" phase with no timeline—a red flag for execution risk.
How the market read it
The stock closed at ₹534.5 ahead of the result announcement on July 18 2026, fell 2.98% on day 1, and extended that decline to 7.07% by day 3. As of July 24 2026, the stock sits at ₹490—a 29% loss from its all-time high and trading below all major moving averages (SMA20 ₹519.89, SMA50 ₹521.42, SMA200 ₹539.31). Foreign institutional investors have trimmed steadily: FII holdings fell from 3.48% in Q1 FY26 to 2.18% in Q4 FY26, a drop of 130 basis points. Domestic institutions flat at ~18%. An insider bulk buy by Bhupesh Kumar Lodha of 2,98,000 shares at ₹491.50 hints at a contrarian boardroom view, though volume is modest. RSI at 31.5 signals mild oversold conditions—technicals could support a rebound, but only if fundamentals stabilize.
Record quarterly revenue (₹697.2 Cr) validates scale and market position
Core B2B at 14% EBITDA margin; diversified portfolio (HPPC, pharma, textiles, animal health)
Export revenue at 23–24% of total, growing 20–21% YoY; stable and profitable
EO supply expected Dec 2026; pharma ramp underway; potential ₹30–50 Cr H2 FY27
Net debt declining (₹248 Cr from ₹280 Cr); asset sales ongoing
Profit growth severely lags revenue (+4.5% vs +28%); QoQ PAT down 23.7%
EBITDA margin miss (11.6% vs 12–13% guidance); down 90 bps year-on-year
Raw material volatility (₹5 Cr phenol loss Q1) and freight spikes unabated; pricing lag
FY27 growth guidance hedged to 15% despite Q1 beat; management tone defensive
B2C exit timeline 2–3 years away; Saudi Arabia in survey phase with no finalized timeline
Thailand plant ramp slow (₹2–3 Cr Q1 from ₹10–15 Cr investment); new ventures dragging profitability
Operating leverage absent; profit growth lags revenue by 23+ points
HighRevenue +28% but PAT +4.5%; QoQ PAT -23.7%. Signals cost inflation and operational drag uncontrolled. This is not a high-quality quarter.
EBITDA margin miss and guidance credibility weakened
High11.6% vs 12–13% prior guidance. Recovery story now pushed 2–3 years out and contingent on B2C exit and utilization gains. Multiple dependencies = execution risk.
Raw material and freight volatility persist; pricing power lag
High₹5 Cr phenol loss Q1. Freight spikes tied to geopolitics. Pricing power exists but lag in pass-through creates margin pressure. Likely to persist near-term.
EO supply shortage caps growth; full ramp only FY28
MediumConstraint persists through Dec 2026. Growth levers limited until then. FY28 will see benefit, but rest of FY27 remains capped.
New ventures (Saudi Arabia, Thailand) early-stage and risky
MediumSaudi Arabia in survey/feedstock allocation stage; no finalization. Thailand yielded only ₹2–3 Cr Q1. Pre-operative drag continues. Timelines uncertain.
Management hedging on macro uncertainty; confidence wavering
MediumFY27 guidance retreated to 15% despite Q1 beat. Tone grew cautious through Q&A. Signals internal uncertainty on delivery and margin recovery.
1 · Q2 profit trajectory and margin hold
Will PAT stabilize near ₹35 Cr or deteriorate further? Will EBITDA margin hold at 11.6% baseline? The 23.7% QoQ decline must reverse by Q2 for the recovery story to hold.
2 · H2 FY27 pharma and aroma ramp delivery
Management guided pharma potential of ₹30–50 Cr H2. Concrete updates on compliance timelines and customer wins will validate or invalidate this guidance.
3 · EO supply arrival and FY28 visibility
December 2026 is the key milestone. If supply arrives as promised, FY28 should see material step-up in utilization and margins. Watch for FY28 guidance by Q3 FY27.
4 · B2C exit progress and debt paydown
₹50 Cr debt tied to B2C. Concrete announcements on asset sales or divestitures will signal execution credibility on the 2–3 year margin recovery plan.
This is a steady quarter masquerading as a beat. Headline revenue is strong, but the underlying profit story is weak: operating leverage has vanished, margins missed guidance, and near-term headwinds remain unabated. Management's retreat on growth guidance and extension of margin timelines suggest internal pressure.
The market's -7% reaction and FII exit are justified. The stock is 29% off its all-time high and oversold on technicals, but fundamentals do not yet support a reversal. An insider bulk buy at ₹491.50 hints at boardroom confidence, but conviction remains untested.
Track organic profit (₹35–37 Cr run-rate) and EBITDA margin recovery (toward 12–13%). Until those improve, the debate remains unresolved. The number to watch from here is quarterly net profit—whether it stabilizes and reverses its QoQ decline. If it does, the margin recovery story lives. If it stalls, execution risk is real.